Emergencies: Clinical Trials

20 trials for Emergencies, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

20 completed. 20 Phase 2, 3 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 220Completed 20
Phase 13Completed 3
Phase 32Completed 2

Follow Emergencies: new trials by email Literature Review of Emergencies trials Research Report on Emergencies

Trials (filtered) newest first · largest first

All 20 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effect of Short-Term Prednisone Therapy on C-Reactive Protein Change in Emergency Department Patients With Acute Heart Failure and Elevated Inflammatory Markers ( CORTAHF )
Prednisone arm, Usual care - Acute Heart Failure
Phase 2 / Phase 3CompletedAssistance Publique - Hôpitaux de Paris32023-02-162026-01-21
Erector Spinae Plane Block for Uncomplicated Renal Colic
Erector Spinae Plane Block (ESPB), Ropivacaine - Renal Colic, Kidney Stone
Phase 2CompletedUniversity of Michigan52023-02-082025-10-30
Restrictive Fluid Administration vs. Standard of Care in Emergency Department Sepsis Patients
Isotonic crystalloids - Sepsis
Phase 2CompletedMarie Kristine Jessen, MD1242021-11-032022-03-25
Non-Steroidal or Opioid Analgesia Use for Children With Musculoskeletal Injuries
Ibuprofen, Acetaminophen, Hydromorphone - Musculoskeletal Injury
Phase 2CompletedUniversity of Alberta7102019-04-202024-09-19
Rapid Agitation Control With Ketamine in the Emergency Department
Ketalar, Midazolam injection, Haloperidol - Violent Aggressive Behavior, Ketamine
Phase 2CompletedDavid Barbic812018-05-292020-11-30
Acute Video-oculography for Vertigo in Emergency Rooms for Rapid Triage (AVERT)
VRT Care - Vertigo, Dizziness
Phase 2CompletedJohns Hopkins University1302017-12-042025-12-26
Comparing Five Oral Analgesics for Treatment of Acute Pain in the Emergency Department (ED)
oxycodone/APAP, hydrocodone/APAP, codeine/APAP - Musculoskeletal Pain
Phase 2CompletedAlbert Einstein College of Medicine6002017-11-282022-02-01
PREMIX vs PREMED Intranasal Lidocaine and Midazolam
Lidocaine, Lidocaine and midazolam (PREMIX), Midazolam - Pain
Phase 2CompletedColumbia University552017-04-032019-09-11
Intranasal Hydromorphone for the Treatment of Acute Pain in Children: A Pilot Study.
Hydromorphone - Pain
Phase 2CompletedColumbia University352015-05-012019-05-28
Nitrous Oxide Analgesia Vaso-occlusive Crisis
Nitrous oxide 50% - Sickle Cell Disease, Vaso-occlusive Crisis
Phase 2CompletedColumbia University52013-11-122026-01-28
Association Between Body Size and Response to Hydromorphone in ED
Hydromorphone - Pain
Phase 2CompletedAlbert Einstein College of Medicine1742011-10-012020-10-08
Intravenous Fluid for Pediatric Migraine in the Emergency Department
Normal saline - Migraine, Headache
Phase 1 / Phase 2CompletedUniversity of Alberta462010-07-012026-02-06
Comparison of Intravenous Cefazolin Plus Oral Probenecid With Oral Cephalexin for the Treatment of Cellulitis
IV cefazolin plus oral probenecid and placebo cephalexin, Oral cephalexin and saline IV plus probenecid placebo - Cellulitis
Phase 2CompletedKelowna General Hospital2062010-05-012018-08-13
Fentanyl Administered Intraorally for Rapid Treatment of Orthopedic Pain
Fentanyl, Lansoprazole, Oxycodone - Pain, Fracture, Sprain
Phase 1 / Phase 2CompletedMassachusetts General Hospital602008-08-012017-02-09
N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients
N-Acetylcysteine (NAC), 0.9% Sodium-chloride - Radiocontrast Nephropathy
Phase 2CompletedBeth Israel Deaconess Medical Center3992007-10-162024-10-29
Lidocaine Patches Prior to Intravenous Insertion
Lidocaine tetracaine, Placebo - Need for Intravenous Catheter
Phase 2CompletedStony Brook University452007-08-012012-10-22
Safety of Hydromorphone in Adult Patients Presenting to the Emergency Department With Acute Severe Pain
2 mg IV hydromorphone - Acute Pain
Phase 2CompletedMontefiore Medical Center2982006-01-012018-08-20
Emergency Department Initiated Tobacco Treatment (EDITT)
Behavior change counseling - Tobacco Use
Phase 1 / Phase 2CompletedNational Institute on Drug Abuse (NIDA)752005-12-012017-01-11
Trial Comparing Morphine to Hydromorphone in Elderly Patients With Severe Pain
Morphine, Hydromorphone - Acute Pain
Phase 2 / Phase 3CompletedMontefiore Medical Center1942005-07-012018-08-20
Safety and Efficacy Study of Hydromorphone and Morphine
Morphine, Hydromorphone - Pain
Phase 2CompletedMontefiore Medical Center1982004-10-012018-08-15

Narrower conditions

Pain (8)  ·  Acute Pain (4)  ·  Aggression (1)  ·  Agnosia (1)  ·  Anemia, Sickle Cell (1)  ·  Benign Paroxysmal Positional Vertigo (1)  ·  Cellulitis (1)  ·  Dizziness (1)  ·  Fractures, Bone (1)  ·  Headache (1)  ·  Hypotension (1)  ·  Kidney Calculi (1)  ·  Lymphoma, Follicular (1)  ·  Migraine Disorders (1)

Broader conditions

Disease Attributes (20)  ·  Pathologic Processes (20)  ·  Pathological Conditions, Signs and Symptoms (20)  ·  Neurologic Manifestations (13)  ·  Signs and Symptoms (13)  ·  Nervous System Diseases (3)  ·  Pain (3)  ·  Behavior (2)  ·  Brain Diseases (2)  ·  Cardiovascular Diseases (2)  ·  Central Nervous System Diseases (2)  ·  Hemic and Lymphatic Diseases (2)  ·  Infections (2)  ·  Inflammation (2)  ·  Vascular Diseases (2)

Interventions

Hydromorphone (6)  ·  Acetaminophen (2)  ·  Ibuprofen (2)  ·  Midazolam (2)  ·  Morphine (2)  ·  Saline Solution (2)  ·  Sodium Chloride (2)  ·  oxycodone-acetaminophen (2)  ·  Acetylcysteine (1)  ·  Behavior Therapy (1)  ·  Cefazolin (1)  ·  Cephalexin (1)  ·  Fentanyl (1)  ·  Haloperidol (1)  ·  Ketamine (1)

Sponsors

Columbia University (3)  ·  Montefiore Medical Center (3)  ·  Albert Einstein College of Medicine (2)  ·  University of Alberta (2)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Beth Israel Deaconess Medical Center (1)  ·  David Barbic (1)  ·  Johns Hopkins University (1)  ·  Kelowna General Hospital (1)  ·  Marie Kristine Jessen, MD (1)  ·  Massachusetts General Hospital (1)  ·  National Institute on Drug Abuse (NIDA) (1)  ·  Stony Brook University (1)  ·  University of Michigan (1)

Countries

United States (14)  ·  Canada (4)  ·  Denmark (1)  ·  France (1)

Top investigators

Andrew K Chang, MD (3)  ·  Daniel S Tsze, MD, MPH (2)  ·  Adam J Singer, MD (1)  ·  Adrienne Birnbaum, MD (1)  ·  Benjamin Friedman, MD (1)  ·  Chris Fung (1)  ·  Daniel Tsze, MD, MPH (1)  ·  David Barbic, MD MSc FRCPC, (1)  ·  David Newman-Toker, MD, PhD (1)  ·  Dawn Dalen, PharmD (1)  ·  Edwin D Boudreaux, PhD (1)  ·  Lawrence P Richer, MD, MSc (1)  ·  Marie K Jessen, MD (1)  ·  Peter Zed, PharmD (1)  ·  Samina Ali, MD (1)

Results publications

PMID 19050988, PMID 23570477, PMID 23769807, PMID 25168404, PMID 26286816, PMID 29914924, PMID 30477544, PMID 30902361, PMID 32565458, PMID 32883371, PMID 33358232, PMID 33675203, PMID 35351214, PMID 35652491, PMID 37023945, PMID 37166022, PMID 41315052, PMID 41505155

NIH funding

U01DC013778 (1)